Human viruses of the herpesviridae family
Publications
Programa de Legionelosis. En Echevarría Mayo JE y Oteo Iglesias J (Editores) Programas de Vigilancia Microbiológica Centro Nacional de Microbiología.
Fernando González-Camacho y Almudena Cascajero. Programa de Legionelosis. En Echevarría Mayo JE y Oteo Iglesias J (Editores) Programas de Vigilancia Microbiológica Centro Nacional de Microbiología. Volumen 2:77-89. 2021-2022 Majadahonda (Madrid); Instituto de Salud Carlos III, Centro Nacional de Microbiología: 2023.
Chikungunya virus infections among travellers returning to Spain, 2008 to 2014
3. Maria Dolores Fernandez Garcia; Mathieu Bangert; Fernando de Ory; Arantxa Potente; Lourdes Hernandez; Fatima Lasala; Laura Herrero; Francisca Molero; Anabel Negredo; Ana Vázquez; Teodora Minguito; Pilar Balfagón; Jesus de la Fuente; Sabino Puente; Eva Ramírez de Arellano; Mar Lago; Miguel Martinez; Joaquim Gascón; Francesca Norman; Rogelio Lopez Velez; Elena Sulleiro; Diana Pou; Nuria Serre; Ricardo Fernández Roblas; Antonio Tenorio; Leticia Franco; Maria Paz Sanchez Seco. Chikungunya virus infections among travellers returning to Spain, 2008 to 2014. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 21 - 36, (Sweden): 08/09/2016. ISSN 1560-7917
PUBMED DOILegionella feeleii: Ubiquitous Pathogen in the Environment and Causative Agent of Pneumonia
Vaccaro L, Gomes TS, Izquierdo F, Magnet A, Llorens Berzosa S, Ollero D, Salso S, Alhambra A, Gómez C, López Cano M, Pelaz C, Bellido Samaniego B, Del Aguila C, Fenoy S, Hurtado-Marcos C. Front Microbiol. 2021;12:707187.
DOIImmunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.
García-Pérez J, Borobia AM, Pérez-Olmeda M, Portolés A, Castaño L, Campins-Artí M, Bertrán MJ, Bermejo M, Arribas JR, López A, Ascaso-Del-Rio A, Arana-Arri E, Fuentes Camps I, Vilella A, Cascajero A, García-Morales MT, Castillo de la Osa M, Pérez Ingidua C, Lora D, Jiménez-Santana P, Pino-Rosa S, Gómez de la Cámara A, De La Torre-Tarazona E, Calonge E, Cruces R, Belda-Iniesta C, Alcamí J, Frías J, Carcas AJ, Díez-Fuertes F. iScience. 2024; 27(9):110728
PUBMED DOILonger intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
García-Pérez J, Bermejo M, Ramírez-García A, De La Torre-Tarazona HE, Cascajero A, Castillo de la Osa M, Jiménez P, Aparicio Gómez M, Calonge E, Sancho-López A, Payares-Herrera C, Layunta Acero R, Vicente-Izquierdo L, Avendaño-Solá C, Alcamí J, Pérez-Olmeda M, Díez-Fuertes F. J Med Virol. 2023; 95(3):e28679
PUBMED DOIImmune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study
Ascaso-Del-Rio A, García-Pérez J, Pérez-Olmeda M, Arana-Arri E, Vergara I, Pérez-Ingidua C, Bermejo M, Castillo de la Osa M, Imaz-Ayo N, Riaño Fernández I, Astasio González O, Díez-Fuertes F, Meijide S, Arrizabalaga J, Hernández Gutiérrez L, de la Torre-Tarazona HE, Mariano Lázaro A, Vargas-Castrillón E, Alcamí J, Portolés A; RescueVac study Group. EClinicalMedicine. 2022; 51:101542
PUBMED DOIAdditional Information
Our group is interested in infections caused by the 8 known human herpes, which are very important etiological agents due to the high rates of infection, as well as their morbidity and mortality, especially in situations in which the immune system is immature (pediatric disease), senescent (pathologies in advanced age) or immunocompromised (transplanted).
They form a very heterogeneous group, but once the infection occurs, it persists for life through its latency phases. The pathogenicity of alpha- and beta-herpesviruses is related to primary infection and its recurrences, but in gamma-herpesviruses their main pathogenicity lies in their ability to produce tumors.
The main objective of the group is to respond to the medical problems caused by these infections from a multidisciplinary point of view, which includes virological, immunological and molecular aspects.
At present, the group's specific research objectives focus mainly on two topics:
Pathogenicity markers in congenital cytomegalovirus disease that modulate the immune system during infection and
Molecular characterization of the varicella zoster virus in cases of vaccine failure. The group's IP is part as a promoter partner of Spin-off: Virnóstica-ISCIII
Our group is interested in infections caused by the 8 known human herpes, which are very important etiological agents due to the high rates of infection, as well as their morbidity and mortality, especially in situations in which the immune system is immature (pediatric disease), senescent (pathologies in advanced age) or immunocompromised (transplanted).
They form a very heterogeneous group, but once the infection occurs, it persists for life through its latency phases. The pathogenicity of alpha- and beta-herpesviruses is related to primary infection and its recurrences, but in gamma-herpesviruses their main pathogenicity lies in their ability to produce tumors.
The main objective of the group is to respond to the medical problems caused by these infections from a multidisciplinary point of view, which includes virological, immunological and molecular aspects.
At present, the group's specific research objectives focus mainly on two topics:
Pathogenicity markers in congenital cytomegalovirus disease that modulate the immune system during infection and
Molecular characterization of the varicella zoster virus in cases of vaccine failure. The group's IP is part as a promoter partner of Spin-off: Virnóstica-ISCIII